Simple Summary Periodontitis, a chronic inflammatory disease of the gums, and the oral
microbiome have been recently implicated in the development of various cancers. Due to …

Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …

Introduction Hepatocellular carcinoma (HCC) is the most common primary liver cancer and
fourth-leading cause of cancer death. While drug discovery to improve disease survival was …

Background Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, which
makes the prognostic prediction challenging. As part of the active cross-talk between the …

Simple Summary Immunotherapy is now the standard front-line therapy for patients with
advanced hepatocellular carcinoma. However, there remains a substantial proportion of …

Simple Summary The investigation of predictive and prognostic markers is pivotal in patients
affected by hepatocellular carcinoma treated with immune-checkpoint-inhibitors …

Hepatocellular carcinoma (HCC) is the most frequent among primary liver tumors (90%) and
one of the main causes of cancer-related death. It develops usually in a chronically inflamed …

Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The
systemic inflammatory response is a pathogenic mechanism shared by cancer progression …

Background and Methods. As a parameter integrating neutrophil (N), lymphocyte (L), and
platelet (P) levels, altered systemic immune‐inflammation index (SII) has been investigated …

Background This study clarified whether EMT-related genes can predict immunotherapy
efficacy and overall survival in patients with HCC. Methods The RNA-sequencing profiles …